- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Differential Diagnosis: Key Features of Demodex Blepharitis
Factors that differentiate Demodex blepharitis apart from other lid margin and ocular surface diseases with overlapping signs and symptoms are examined.
EP: 1.Overview of Demodex Blepharitis
EP: 2.Pathophysiology of Demodex Blepharitis
EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice
EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis
EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis
EP: 6.Treatment of Demodex Blepharitis
EP: 7.Diagnosis and Prevalence of Demodex Blepharitis
EP: 8.Exploring a Recently Approved Therapy for Demodex
EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis
EP: 10.Outlook on the Future of Demodex Blepharitis Treatment
EP: 11.Understanding Demodex Blepharitis Pathogenesis
EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment
EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment
This is a video synopsis/summary of a discussion involving Elizabeth Yeu, MD.
Yeu discusses how Demodex blepharitis shares some nonspecific symptoms with other lid and ocular surface diseases, such as irritation, foreign body sensation, and watery eyes. However, patients with Demodex blepharitis uniquely have worse morning symptoms and itching or matting of the eyelids. She states that slit lamp exam showing pathognomonic debris extrusion can help distinguish Demodex blepharitis from lookalike conditions when paired with the characteristic symptoms. Citing data from the TITAN study of over 1000 patients at 7 US clinics and a separate 200-patient study by Eric Rosenberg, DO, MSE, Yeu notes a Demodex blepharitis prevalence of 50% to 58% among patients presenting to eye care offices. She emphasizes that the disease is common enough to warrant a high index of suspicion and deliberate diagnostic approach, differentiating it from similar inflammatory conditions.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
